Alkermes plc — Earnings Quality Grade C
ALKS · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 66 days, change -7 days YoY
AR growth -14.8% vs revenue growth -5.2%
Revenue -5.2%, CFFO 18.6%. Cash follows revenue
Expense Quality
Inventory growth 7.5% far exceeds COGS -19.9%, margin rising. Fraud signal
CapEx growth 20.7% is >2x revenue growth -5.2%
SG&A/Gross Profit = 54.8%. Normal
Gross margin 86.7%, change +2.4pp. Stable
Cash Flow Quality
CFFO/NI = 2.15. Profits backed by cash
FCF $0.5B, FCF/NI = 1.99
Accruals ratio = -11.2%. Low accruals
Cash $0.6B covers debt $0.1B
Balance Sheet Health
Goodwill+Intangibles $0.1B = 5% of equity. Manageable
Debt/EBITDA = 0.2x. Healthy
Other assets grew 197.5% vs revenue -5.2%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -0% YoY. Normal
Manipulation Score
M-Score = -3.31 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor ALKS continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25